Global CyberKnife Market Size, Trend & Opportunity Analysis Report, by Application (Tumour, Cancer, Vascular Malformation), End Use (Hospitals, Outpatient Facilities, Research & Manufacturing), and Forecast, 2025-2035
Global CyberKnife Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global CyberKnife Market was valued at USD 637.4 million in 2024 and is anticipated to reach USD 3,792.21 million by 2035, expanding at a CAGR of 17.6% during the forecast period 2025-2035. Traditionally, radiation oncology and neurosurgery have been based on imprecise treatment methods. However, the technological revolution in the healthcare ecosystem has given rise to CyberKnife-like precision treatment modalities, bringing new definitions to the discipline. The cutting-edge device is an advanced robotic radiosurgery system that has acquired a pivotal position for the non-invasive treatment of tumours, cancers, and vascular malformations. Its acceptance was strongly propelled by the ever-increasing burden of cancer in the world, combined with the clinical urge for targeted therapies with an extremely high degree of accuracy and with minimal collateral damage to host tissues.
The rising rates of brain, lung, prostate, and liver cancers have similarly called for radiation technology that shall spare damage and maximise survival probabilities for the patients. The commercial applicability of the CyberKnife systems fits in tightly with the clinical demands of robotic accuracy and real-time imaging. As hospitals and outpatient clinics begin to integrate the CyberKnife procedure with various treatment pathways due to the system's ability to deliver hypofractionated radiation doses without surgical incision, its use will increase. Additionally, with the convergence of artificial intelligence and image-guided robotics, cytokinesis elevated targeting performance with sub-millimetre accuracy.
On the supply side, an accelerated wave of collaboration between device manufacturers, oncology centres, and research institutes is underway toward improving treatment protocols and increasing clinical acceptance. Not only are technology upgrades shaping the competitive landscape of CyberKnife systems, but also the regulatory approvals and capital investment in cancer treatment infrastructure worldwide. The emerging markets are strategically positioning the CyberKnife system toward two major objectives: to better healthcare and attract international patients under medical tourism. Hence, the global market for CyberKnife systems is transitioning toward mainstream acceptance, fundamentally altering cancer care at the interface of robotics, radiation, and precision medicine.
Recent Developments in the Industry
- In March 2024, Accuray Incorporated announced an update for workflow solutions within the CyberKnife platform with artificial intelligence integration for fast treatment planning and execution. This innovation is targeting the reduction of the clinician's workload while maintaining treatment accuracy.
- In June 2024, Elekta AB associated with distinguished academic hospitals across Europe and North America to run multi-centre trials assessing the long-term clinical efficacy of CyberKnife-based radiosurgery in brain metastases and prostate cancers.
- In February 2025, Varian Medical Systems, a Siemens Healthineers company, launched an integrated software suite aimed at enhancing interoperability between imaging platforms and CyberKnife treatment systems, thus decreasing planning time and increasing treatment accuracy.
- In August of 2023, Brainlab AG collaborated with multiple cancer research institutions to begin the exploration of adaptive treatment techniques within CyberKnife systems, with the goal of dynamically personalising treatment plans based on tumour response data.
- In May 2024, Zap Surgical Systems received FDA clearance of its Zap-X Gyroscopic Radiosurgery system, a direct competitor with CyberKnife technology in the neurosurgical radiosurgery market.
Market Dynamics
The world's effort needs to be in the direction of promising research advancement and improvement in radiotherapy technique.
These phenomena in extra open-up use are an increase in patient reluctance to spend periods in the hospital, creating high public demand for such procedures dependence on long stays in the hospital.
Implementation of incentives and other regulations would boost the market.
Countries and health bodies have started recognising robotic radiosurgery as a major area in oncology treatment. Exceptions regarding the reimbursement structures, as well as fast FDA/CE approval, exist in places such as the USA and Europe, allowing for quick installations. This regulatory momentum creates the push needed to adopt in developing markets that were previously denied on reimbursement grounds.
Most hospitals cannot afford the very large capital investments
Although the CyberKnife has significant clinical benefit potential, it is a capital-intensive investment. Funding for acquiring such high-end equipment is a big challenge for most hospitals in the developing world. The operational costs of maintenance and personnel training only complicate this problem further.
Medical tourism and opening up outpatient centres
On the outpatient front, the upscale investments into medical tourism are coalescing into fresh demand pockets. The fresh demand pockets that are emerging through Invest in Now and the emerging economies in Asia-Pacific and the Middle East will use CyberKnife adoption not only to build capacities for domestic demand but also to attract international patients in wealthier countries.
The future of radiosurgery will be more about AI combined with robotics and image guidance.
The integration of innovative developments, including artificial intelligence, real-time imaging, and adaptive treatment models, will revolutionise the CyberKnife system's treatment paradigm in oncology. This will increase accuracy, shorten treatment cycles, and improve patient outcomes, ensuring longer sustainability of the market.
Attractive Opportunities in the Market
- AI-Driven Workflows - AI-enhanced planning and imaging boost treatment accuracy and clinical efficiency.
- Medical Tourism Growth - CyberKnife adoption in Asia and the Middle East supports global patient inflow.
- Outpatient Facility Expansion - Ambulatory centres are rapidly integrating robotic radiosurgery services.
- Cancer Prevalence Surge - Rising global cancer incidence ensures long-term demand for CyberKnife.
- Collaborative Research Models - Partnerships with hospitals accelerate adaptive treatment advancements.
- Reimbursement Acceleration - Growing insurance coverage and policy support drive wider accessibility.
- Emerging Market Penetration - Expanding installations in APAC and LAMEA spur fresh revenue streams.
- Integration with Imaging Systems - Interoperability with MRI/CT enhances treatment planning precision.
- FDA and CE Approvals - Regulatory clearances enable faster clinical adoption across key regions.
- Patient-Centric Innovation - Shorter recovery times strengthen patient preference over invasive methods.
Report Segmentation
By Application: Tumour, Cancer, Vascular Malformation
By End Use: Hospitals, Outpatient Facilities, Research & Manufacturing
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Accuray Incorporated, Elekta AB, Varian Medical Systems (Siemens Healthineers), Brainlab AG, ViewRay Inc., Zap Surgical Systems, GE Healthcare, Hitachi Ltd., Philips Healthcare, and Mevion Medical Systems.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 293
Dominating Segments
By then, CyberKnife would have treated a major segment of tumours as the oncology burden increases all over the world.
CyberKnife has transformed the health care landscape, with more patients and health practitioners calling for solutions that balance efficacy with quality of life. Cancer remains the driving force behind CyberKnife adoption. Several types of cancer, especially prostate, lung, and brain cancers, account for the largest share of cases treated with CyberKnife systems. The high level of sophistication involved in this device-hypofractionated-targeted treatment, which does not require invasive procedures or long recovery times, makes this modern oncology so indispensable.
Non-invasive radiosurgery applications for tumours are becoming a hot trend.
Benign and malignant tumours in delicate areas such as the brain and spine have been examples of the major clinical drivers of CyberKnife. This was the reason why neurosurgeons and oncologists opted for this system. Patients under CyberKnife treatment for AVMs or similar vascular problems should benefit most from low-risk nonsurgical methods. This significant increase in the use of CyberKnife has also been seen at hospitals worldwide, most of which do not have resource options for more complex treatments.
Changing vascular malformations to a niche but important application
Vascular malformation treatment is gradually growing with CyberKnife, although it has a small contribution to the total revenue of the market. Precision radiosurgery that benefits patients who have arteriovenous malformations (AVMs) and other vascular anomalies provides a safer alternative to conventional surgery. Along with research on long-term effectiveness, this segment shows a lot of promise for high growth over the course of the forecast period.
Hospitals take up a dominant share of CyberKnife installations among end-use settings.
Hospitals continue to be the leading adopters of CyberKnife systems, given their capability to fund higher levels of capital investments as well as their potential to tie together multidisciplinary oncology departments. Such institutions that adopt this forward-looking approach are typically leading cancer institutes or academic hospitals, aided by grants, government investments, and research collaborations.
Outpatient facilities will now grow fast, thanks to low-cost delivery models.
Outpatient centres have sprung up as one of the fastest-growing end-use segments as health systems attempt to decentralise high-cost treatments. With CyberKnife treatment cycles becoming shorter and requiring fewer inpatient days, the system is becoming ever more suited to outpatient adoption, increasing both patient and provider attraction.
Research institutes and device manufacturers drive the innovation pipeline
Further, research institutions and device manufacturers are at the forefront of expanding the clinical indications for CyberKnife and fine-tuning the treatment. Such institutions are facilitating knowledge transfer and propelling product innovation through multicenter trials and investments in adaptive radiosurgery protocols.
Key Takeaways
- Cancer Care Leadership - Oncology applications dominate due to precision-focused treatment demand.
- Hospital Segment Strength - Hospitals remain the core adopters of CyberKnife installations worldwide.
- Outpatient Growth Surge - Ambulatory centres are emerging as fast-growing treatment providers.
- Tumour Applications Rising - Radiosurgery adoption expands for complex brain and spine tumours.
- Vascular Malformation Potential - Expanding treatment scope promises niche but critical market growth.
- APAC Growth Momentum - Infrastructure investments accelerate CyberKnife installations across Asia-Pacific.
- AI-Powered Precision - Integration of artificial intelligence enhances treatment planning and delivery.
- Regulatory Acceleration - Faster FDA and CE approvals improve adoption rates in developed markets.
- Medical Tourism Boost - Patient inflow in APAC and the Middle East fuels regional adoption growth.
- Innovation Pipeline Strong - Research collaborations drive next-generation radiosurgery advancements.
Regional Insights
Even on CyberKnife for Oncology Support, North America remains at the head of CyberKnife adoption.
CyberKnife is a dominant area in the North American region, primarily due to the US's mature oncology settings, increasing cancer incidence, and favourable reimbursement policies. Continuous adoption and usage are ensured by the presence of key manufacturers and the existence of advanced healthcare institutions. Furthermore, huge investments in AI-based platforms for treatment provision supplement the region's preeminence in precision radiosurgery.
Europe evolves in establishing itself as a greenfield hub for precision medicine and clinical collaborations.
Europe can stand up to having the highest high-technology quality in clinical trials and produces the most innovative medical devices, thus making it in a favourable position to become the largest market for CyberKnife by countries such as Germany, France, and the UK, which invest in formative years in adaptive radiosurgery trials and integrate CyberKnife into the national health system. Regulatory frameworks and other hospital networks for collaboration have an allure in increasing the pace of their adoption in the oncology care pathway.
Asia-Pacific tops the race as the fast-growing region that could witness a significant upsurge in the demand to address cancer care.
APAC will have dramatic growth with increasing cancer incidence, expanding health infrastructure, and government-directed investments in modern oncology care. Leadership within the installations would typically be from Persian China, India, and South Korea, coupling the installation of CyberKnife with medical tourism efforts that would bring in international patients.
LAMEA develops entry prospects for emerging oncology infrastructures in medical tourism.
Latin America, the Middle East, and Africa are adopting the CyberKnife systems with more enthusiasm because of increasing medical tourism to these regions and expanding networks of oncology. While countries like the UAE and Saudi Arabia are engaged in positioning themselves as hubs for international patients, Brazil and Argentina are adopting this technology more gradually under healthcare modernisation programs.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
The market is primarily driven by the treatment of cancers (specifically prostate, lung, and brain cancers), various benign and malignant tumors in delicate areas like the spine, and vascular malformations such as arteriovenous malformations (AVMs). Cancer care remains the dominant application due to the system's ability to deliver high-precision, non-invasive treatment.
AI is being integrated to enhance workflow solutions, fast-track treatment planning, and improve execution. Recent developments, such as Accuray’s 2024 AI update, aim to reduce clinician workloads while maintaining sub-millimeter targeting accuracy and enabling real-time adaptive treatment models.
Hospitals currently hold the dominant share of CyberKnife installations. This is due to their ability to manage high capital investments, integrate multidisciplinary oncology departments, and leverage government grants or research collaborations. However, outpatient facilities are emerging as the fastest-growing segment due to the shift toward decentralized, cost-effective care.
The primary challenges include high capital expenditure requirements for initial installation, significant operational costs for maintenance, and the need for specialized personnel training. These financial hurdles particularly impact hospital adoption in developing economies.
North America currently leads the market due to mature oncology settings and favorable reimbursement policies. Meanwhile, the Asia-Pacific (APAC) region is expected to be the fastest-growing market, driven by expanding healthcare infrastructure, rising cancer incidence, and a surge in medical tourism in countries like China and India.
Emerging markets in the Middle East (such as UAE and Saudi Arabia) and Asia-Pacific are strategically installing CyberKnife systems to attract international patients. These regions are positioning themselves as high-tech hubs for precision medicine, offering advanced radiosurgery to patients from wealthier countries seeking efficient, non-invasive treatments.
The competitive landscape includes major players such as Accuray Incorporated, Elekta AB, Varian Medical Systems (a Siemens Healthineers company), Brainlab AG, ViewRay Inc., Zap Surgical Systems, GE Healthcare, Hitachi Ltd., Philips Healthcare, and Mevion Medical Systems.
Key developments include Varian’s 2025 launch of an interoperable software suite to decrease planning time, Brainlab’s exploration of adaptive treatment techniques, and Zap Surgical Systems’ FDA clearance for the Zap-X Gyroscopic Radiosurgery system, which serves as a direct competitor to CyberKnife.
CyberKnife offers a non-invasive alternative that delivers hypofractionated radiation doses with sub-millimeter accuracy. This results in minimal collateral damage to healthy host tissues, eliminates the need for surgical incisions, and significantly reduces patient recovery times and hospital stays.
